Aquavit Files Extra IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis
NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the therapy of palmar hyperhidrosis applying its patented microchannel technologies™. DTX-024 is a extremely purified and clinically tested injectable neuromodulator derived from neurotoxins created by Clostridium botulinum.
Aquavit Logo (PRNewsfoto/Aquavit Pharmaceuticals, Inc.)
Alongside Aquavit’s biosimilar plan for its botulinum toxin, this will be the initial in the globe, indicated for palmar hyperhidrosis, authorized by FDA.
Aquavit has been investing in proprietary delivery technologies and connected intellectual house for botulinum toxin. This is a strategic move that puts them ahead of the curve in the speedy-expanding multi-billion-dollar botulinum toxin marketplace.
To successfully execute the approach, Aquavit has lately bolstered its executive group with seasoned veterans from the sector and the academia.
Dr. David Crean, PhD, MBA has been named Chief Monetary Officer of Aquavit Holdings. He has get- and sell-side knowledge in mergers & acquisitions (M&A), partnering and investments inside the life sciences and healthcare sectors operating inside strategic biopharmaceutical corporations, private equity, investment banking and venture capital. He commenced his profession inside biopharmaceutical corporations far more than 30 years ago, most notably at Allergan, an Abbvie Organization, exactly where he lead deal execution for each technologies, item, and business acquisitions and divestitures across a broad variety of therapeutic locations and enterprise units like injectable and topical healthcare aesthetics, dermatology, neurology, and ophthalmology. He serves on quite a few boards like each public and private corporations and has been awarded a lot of recognitions like San Diego’s 500 Most Influential men and women for the previous 4 years (2019 -2022), 2020 Best Believed Leaders by Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Story continues
Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Healthcare Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of knowledge and expertise to scientific developments, drug improvement and approval, and new drug discovery. He holds his degrees from University of Oxford and Harvard Healthcare College and presently holds an academic position at Columbia Healthcare College.
With Aquavit’s verified track record of building and launching international brands, such as AQUAGOLD®, the business has demonstrated their capacity to effectively bring revolutionary goods to marketplace. With their deep expertise of botulinum toxin and substantial network of physicians, Aquavit is properly-positioned to make a substantial influence in the sector.
“The neurotoxin marketplace is expanding quickly, with growing demand for revolutionary goods and customized therapy plans. There is presently no FDA approval for palmar hyperhidrosis and by means of our novel route of administration we will be capable to give new options to meet the evolving wants of sufferers in pathologies that are particularly debilitating. The provision of access for this population is a step in the proper path towards enhancing their overall health and properly-getting. ” Churl-Su Kwon, CMO Aquavit.
About Aquavit
Aquavit is an revolutionary healthcare business that supplies a extensive variety of proprietary pharmaceutical, biotech and healthcare device technologies. Aquavit focuses on customized medicine to strengthen patients’ overall health, maximize the efficiency of our healthcare neighborhood, and assistance the pharmacoeconomics of payers.
Cision
View original content material to download multimedia:https://www.prnewswire.com/news-releases/aquavit-files-extra-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technologies-for-palmar-hyperhidrosis-301775589.html
Supply Aquavit Holdings
